-
Something wrong with this record ?
Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy
M. Záleský, J. Stejskal, V. Adamcova, J. Hrbáček, I. Minarik, A. Pavlicko, J. Votrubova, M. Babjuk, R. Zachoval,
Language English Country Switzerland
Document type Journal Article
Grant support
NV15-27047A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Medline Complete (EBSCOhost)
from 1998-01-01 to 1 year ago
PubMed
31067560
DOI
10.1159/000500350
Knihovny.cz E-resources
- MeSH
- Biopsy * MeSH
- Early Detection of Cancer standards MeSH
- Medical Oncology standards MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiparametric Magnetic Resonance Imaging * MeSH
- Prostatic Neoplasms diagnostic imaging pathology MeSH
- Prostate pathology MeSH
- Prostate-Specific Antigen blood MeSH
- Reproducibility of Results MeSH
- Decision Making MeSH
- Aged MeSH
- Ultrasonography MeSH
- Image-Guided Biopsy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Multi-parametric magnetic resonance imaging (mpMRI)-directed biopsy for prostate cancer (PC) diagnosis improves the detection of clinically significant prostate cancer (CSPC) and decreases the rate of over-diagnosis of insignificant disease. The aim of this study was to investigate the value of mpMRI combined with prostate specific antigen density (PSAD) in the decision making related to the biopsy. METHODS: mpMRI and mpMRI/transrectal ultrasound fusion targeted biopsies with subsequent systematic biopsies were performed in 397 patients (223 biopsy-naïve and 174 with a previous biopsy). Detection rates of (CSPC) and insignificant PC were stratified using the PIRADS score, and the number of avoidable biopsies and missed (CSPC) were plotted against PSAD values of 0.1-0.5 ng/mL2. RESULTS: PIRADS <3 and PSAD <0.2 ng/mL2 were the safest criteria for not performing a biopsy. When applied to the biopsy-naïve group, 21.5% (48/223) of the biopsies could have been avoided and 3.7% (3/82) of CSPC would have been missed. In the repeat biopsy group, 12.6% (22/174) of biopsies could have been avoided and 6.9% (4/58) of (CSPC) would have been missed. CONCLUSIONS: A combination of mpMRI and PSAD might reduce the number of biopsies performed with the cost of missing <4% of CSPC.
2nd Faculty of Medicine Department of Urology Charles University Prague Czechia
Department of Radiology Thomayer Hospital Prague Czechia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006389
- 003
- CZ-PrNML
- 005
- 20200522093551.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000500350 $2 doi
- 035 __
- $a (PubMed)31067560
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Záleský, Miroslav $u Department of Urology, Thomayer Hospital, Prague, Czechia. 1st Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
- 245 10
- $a Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy / $c M. Záleský, J. Stejskal, V. Adamcova, J. Hrbáček, I. Minarik, A. Pavlicko, J. Votrubova, M. Babjuk, R. Zachoval,
- 520 9_
- $a BACKGROUND: Multi-parametric magnetic resonance imaging (mpMRI)-directed biopsy for prostate cancer (PC) diagnosis improves the detection of clinically significant prostate cancer (CSPC) and decreases the rate of over-diagnosis of insignificant disease. The aim of this study was to investigate the value of mpMRI combined with prostate specific antigen density (PSAD) in the decision making related to the biopsy. METHODS: mpMRI and mpMRI/transrectal ultrasound fusion targeted biopsies with subsequent systematic biopsies were performed in 397 patients (223 biopsy-naïve and 174 with a previous biopsy). Detection rates of (CSPC) and insignificant PC were stratified using the PIRADS score, and the number of avoidable biopsies and missed (CSPC) were plotted against PSAD values of 0.1-0.5 ng/mL2. RESULTS: PIRADS <3 and PSAD <0.2 ng/mL2 were the safest criteria for not performing a biopsy. When applied to the biopsy-naïve group, 21.5% (48/223) of the biopsies could have been avoided and 3.7% (3/82) of CSPC would have been missed. In the repeat biopsy group, 12.6% (22/174) of biopsies could have been avoided and 6.9% (4/58) of (CSPC) would have been missed. CONCLUSIONS: A combination of mpMRI and PSAD might reduce the number of biopsies performed with the cost of missing <4% of CSPC.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a biopsie $7 D001706
- 650 _2
- $a rozhodování $7 D003657
- 650 _2
- $a časná detekce nádoru $x normy $7 D055088
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ultrazvukem navigovaná biopsie $7 D061705
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lékařská onkologie $x normy $7 D008495
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a multiparametrická magnetická rezonance $7 D000081364
- 650 _2
- $a prostata $x patologie $7 D011467
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a nádory prostaty $x diagnostické zobrazování $x patologie $7 D011471
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a ultrasonografie $7 D014463
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stejskal, Jiri $u Department of Urology, Thomayer Hospital, Prague, Czechia.
- 700 1_
- $a Adamcova, Vanda $u Department of Urology, Thomayer Hospital, Prague, Czechia.
- 700 1_
- $a Hrbáček, Jan $u Department of Urology, Thomayer Hospital, Prague, Czechia.
- 700 1_
- $a Minarik, Ivo $u 2nd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
- 700 1_
- $a Pavlicko, Adam $u Department of Radiology, Thomayer Hospital, Prague, Czechia.
- 700 1_
- $a Votrubova, Jana $u Department of Radiology, Thomayer Hospital, Prague, Czechia.
- 700 1_
- $a Babjuk, Marek $u 2nd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
- 700 1_
- $a Zachoval, Roman $u Department of Urology, Thomayer Hospital, Prague, Czechia, roman.zachoval@ftn.cz. 1st Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia, roman.zachoval@ftn.cz. 3rd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia, roman.zachoval@ftn.cz.
- 773 0_
- $w MED00004616 $t Urologia internationalis $x 1423-0399 $g Roč. 103, č. 1 (2019), s. 33-40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31067560 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200522093549 $b ABA008
- 999 __
- $a ok $b bmc $g 1525247 $s 1096445
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 103 $c 1 $d 33-40 $e 20190508 $i 1423-0399 $m Urologia internationalis $n Urol Int $x MED00004616
- GRA __
- $a NV15-27047A $p MZ0
- LZP __
- $a Pubmed-20200511